You are here: Industry Insights > Keytruda

News List

OncoSec and Merck to Evaluate Combination of ImmunoPulse IL-12 and Keytruda for Metastatic Melanoma americanpharmaceuticalreview
May 11, 2017
OncoSec Medical entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec's ImmuoPulse IL-12 with Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in a Phase II clinical trial, referred to as PISCES.
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma pharmaceutical-technology
May 09, 2017
Merck has received approval from the European Commission (EC) for Keytruda (pembrolizumab) to treat adult patients affected with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab
First approval for Keytruda in a hematologic malignancy in the EU cphi-online
May 08, 2017
European Commission approves Keytruda for patients with relapsed or refractory classical Hodgkin lymphoma who failed ASCT and BV or who are transplant-ineligible and have failed BV.
Atara Bio, Merck in Clinical Combo Alliance contractpharma
April 24, 2017
Atara to evaluate its ATA129 with Merck’s Keytruda
EMA’s CHMP Recommends Approval of Merck’s KEYTRUDA® for the Treatment of Patients with Relapsed or R americanpharmaceuticalreview
March 27, 2017
Merck has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab).
FDA Approves Merck’s KEYTRUDA® for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL americanpharmaceuticalreview
March 17, 2017
Merck has announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy.
FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL) drugs.com
March 15, 2017
Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL).
Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC cphi-online
February 06, 2017
First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.
Merck agrees to resolve Keytruda patent infringement litigation pharmaceutical-technology
January 24, 2017
US-based Merck and associated affiliates have entered an agreement with Bristol-Myers Squibb and Ono Pharmaceutical, to resolve Keytruda (pembrolizumab) patent litigation.
Merck announces settlement and license agreement resolving KEYTRUDA financialexpress
January 24, 2017
The company will make a one-time payment of $625 million to Bristol-Myers Squibb and provide royalties on the worldwide sales of KEYTRUDA

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page